[Corrigendum] DR2 blocker thioridazine: A promising drug for ovarian cancer therapy

Yong,Min; Yu,Tinghe; Tian,Si; Liu,Shuaibin; Xu,Jiao; Hu,Jianguo; Hu,Lina

doi:10.3892/ol.2020.11285

March-2020 Volume 19 Issue 3

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

March-2020 Volume 19 Issue 3

Full Size Image

Correction Open Access

[Corrigendum] DR2 blocker thioridazine: A promising drug for ovarian cancer therapy

Authors:
- Min Yong
- Tinghe Yu
- Si Tian
- Shuaibin Liu
- Jiao Xu
- Jianguo Hu
- Lina Hu
View Affiliations / Copyright

Affiliations: Department of Obstetrics and Gynecology, Affiliated Hospital of North Sichuan Medical College, Nanchong, Sichuan 637000, P.R. China, Department of Obstetrics and Gynecology, Second Affiliated Hospital, Chongqing Medical University, Chongqing 400010, P.R. China, Department of Rehabilitation, Second Affiliated Hospital, Chongqing Medical University, Chongqing 400010, P.R. China

Copyright: © Yong et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY 4.0].
Pages: 2072-2072
|
Published online on: January 9, 2020

https://doi.org/10.3892/ol.2020.11285
Expand metrics +

Article

Oncol Lett 14: [Related article:] 8171-8177, 2017; DOI: 10.3892/ol.2017.7184

Subsequently to the publication of the above article, the authors have realized that Figs. 1 and 2 contained incorrect GAPDH control bands; in particular, the same GADPH bands had erroneously been included twice in Fig. 2 for experiments that involved two different cell lines. These GAPDH bands were included inadertently in this pair of figures owing to a mislabelling of the original data files.

Figure 1.

Thioridazine blocked DR2 and suppressed cell proliferation. (A) The effect of thioridazine on cell proliferation; a concentration of 15 µM was the minimum required to induce the inhibition of SKOV3 and A2780 cells. Data are presented as the mean ± standard derivation of three independent experiments. *P=0.003; **P=0.009 vs. control. (B) Light microscopy images of ovarian cancer cell morphology following treatment with 15 µM thioridazine for the designated length of time (0, 6, 12 and 24 h). Scale bar, 100 µm. (C) DR2 expression as determined by western blotting analysis. GAPDH was used as the reference. Bar graph represents the mean ± standard deviation of triplicate experiments. *P=0.019, **P=0.038, compared with the control group.

Figure 2.

Thioridazine-induced apoptosis. (A) Annexin V/PI double staining analysis of SKOV3 and A2780 cells treated with or without 15 µM thioridazine. Data are representative of the results of triplicate independent experiments. *P=0.01, **P=0.005, compared with the control group. (B) Representative western blotting demonstrating the levels of cleaved caspase-3. GAPDH was used as an internal control. Bar graph represents the mean ± standard deviation of triplicate experiments. *P=0.041, 12 h; **P=0.012, 24 h; ***P=0.044, 12 h; ****P=0.026, 24 h, vs. control group. PI, protease inhibitor; NC, negative control.

The corrected versions of Figs. 1 and 2, as they should have appeared in the Journal, are shown opposite. All the authors agree to this Corrigendum. Note that the revisions made to these figures do not adversely affect the results reported in the paper, or the conclusions stated therein. The authors regret that these errors were not noticed prior to the publication of this article, and offer their apologies to the Editor and to the readers of the Journal.

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

[Corrigendum] DR2 blocker thioridazine: A promising drug for ovarian cancer therapy

This article is mentioned in:

Article

Figure 1.

Figure 2.

Related Articles